New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

iX Biopharma New York California

Sublingual NAD+ is the new gold standard for daily NAD+ supplementation, without the need for precursorsand through select specialist clinics in Singapore.

About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of pharmaceutical drugs and innovative nutraceuticals using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a number of drug delivery platform technologies, including WaferiX, WaferlogiX and NADiX, which deliver small molecule and biologics sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The drug delivery platforms are particularly useful for drug repurposing, where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. iX Biopharma's portfolio includes among others, ketamine, dexmedetomidine, medicinal cannabis and nutraceuticals designed to improve healthspan and longevity.

View original content:https://www.prnewswire.co.uk/news-releases/new-study-demonstrates-that-sl-nad-delivers-nad-into-cells-302235592.html